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Tumor necrosis factor superfamily
Tumor necrosis factor receptor superfamilyAPRIL (A Proliferation-Inducing Ligand, TNFSF13) is a member of the tumor necrosis factor superfamily that reg-
ulates lymphocyte survival and activation and has been implicated in tumorigenesis and autoimmune diseases.
Here we report the expression and ﬁrst known activity of APRIL in the nervous system. APRIL and one of its
receptors, BCMA (B-Cell Maturation Antigen, TNFRSF17), are expressed by hippocampal pyramidal cells of
fetal and postnatal mice. In culture, these neurons secreted APRIL, and function-blocking antibodies to either
APRIL or BCMA reduced axonal elongation. Recombinant APRIL enhanced axonal elongation, but did not inﬂu-
ence dendrite elongation. The effect of APRIL on axon elongationwas inhibited by anti-BCMA and the expression
of a signaling-defective BCMA mutant in these neurons, suggesting that the axon growth-promoting effect of
APRIL is mediated by BCMA. APRIL promoted phosphorylation and activation of ERK1, ERK2 and Akt and serine
phosphorylation and inactivation of GSK-3β in cultured hippocampal pyramidal cells. Inhibition of MEK1/MEK2
(activators of ERK1/ERK2), PI3-kinase (activator of Akt) or Akt inhibited the axon growth-promoting action of
APRIL, as did pharmacological activation of GSK-3β and the expression of a constitutively active form of
GSK-3β. These ﬁndings suggest that APRIL promotes axon elongation by a mechanism that depends both
on ERK signaling and PI3-kinase/Akt/GSK-3β signaling.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
The 19 members of the tumor necrosis factor superfamily (TNFSF)
are best understood for theirmany critical functions in the development
and function of the immune system, but are increasingly recognized as
having diverse roles in other tissues and organs (Hehlgans and Pfeffer,
2005). These cytokines are type II transmembrane glycoproteins that
are generally active both as membrane-bound ligands and as soluble
ligands following cleavage from the cell membrane by the action of spe-
ciﬁc metalloproteinases. TNFSF ligands bind to one or moremembers of
the TNF receptor superfamily (TNFRSF) (Grivennikov et al., 2006).
Recentwork has shown that several TNFSF proteins are able tomod-
ulate neurite growth from developing neurons. For example, in certain
neurons, soluble FasL and GITRL enhance neurite growth (Desbaratsska Institute, 17177 Stockholm,
. This is an open access article underet al., 2003; O'Keeffe et al., 2008; Zuliani et al., 2006) whereas soluble
LIGHT, TNF and RANKL reduce neurite growth (Gavalda et al., 2009;
Gutierrez et al., 2008, 2013; Neumann et al., 2002). Reverse signaling
via membrane integrated TNF has also recently been shown to promote
sympathetic axon growth and tissue innervation (Kisiswa et al., 2013).
APRIL (A Proliferation-Inducing Ligand, TNFSF13) is amember of the
TNFSF that was ﬁrst characterized for its ability to promote tumor
growth (Hahne et al., 1998), but is best characterized for its role in
regulating lymphocyte survival and activation (Schneider, 2005).
APRIL has also been implicated in the etiology and/or maintenance of
a variety of autoimmune diseases (Dillon et al., 2006). In addition to
its synthesis by a variety of cells of the immune system (Craxton et al.,
2003; Litinskiy et al., 2002; Schwaller et al., 2007), APRIL has also been
detected in adipocytes, keratinocytes and osteoclasts (Alexaki et al.,
2009; Hemingway et al., 2011; Pelekanou et al., 2008). APRIL is unusual
among the TNFSF in not being expressed at the cell surface as a
membrane-anchored protein, but is processed in the Golgi apparatus
by a furin-convertase enzyme to generate a biologically active, se-
creted protein (Lopez-Fraga et al., 2001).
APRIL binds two TNFRSF members, BCMA (B-Cell Maturation Anti-
gen, TNFRSF17) and TACI (Transmembrane Activator and Cyclophilin
Ligand, TNFRSF13B) (Bossen and Schneider, 2006), and can also bind
to the proteoglycan syndecan-1 (Hendriks et al., 2005; Ingold et al.,the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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TNFSF13B) also binds to BCMA and TACI and to another TNFRSF mem-
ber BAFFR (BAFF receptor, TNFRSF13C) (Vincent et al., 2013). However,
whereas APRIL binds strongly to BCMA and moderately to TACI, BAFF
binds weakly to BCMA and strongly to TACI and BAFFR (Day et al.,
2005).
Expression of APRIL in the nervous system has not previously been
reported and APRIL has no known function in the developing or mature
nervous system. As part of our ongoing investigation of the potential
roles of members of the TNFSF in neural development, an expression
screen revealed the presence of APRIL in the developing hippocampus,
which was the starting point of the studies reported here. We focused
on the potential effect of APRIL on the development of hippocampal py-
ramidal neurons, not least because these neurons are easily isolated and
studied in vitro and are among the most extensively characterized
models for investigating the differentiation and growth of axons and
dendrites in the developing mammalian central nervous system
(Bradke and Dotti, 2000; Dotti et al., 1988; Kaech and Banker, 2006;
Kaech et al., 2012; Spruston, 2008). These large excitatory neurons
receive very large numbers of excitatory and inhibitory synaptic inputs
andproject to neuronswithin and beyond thehippocampus (Piskorowski
and Chevaleyre, 2012). In rodents, they are generated during embryonic
development and extend axons and elaborate dendrites during late fetal
and early postnatal development (Danglot et al., 2006). We ﬁnd that
APRIL selectively enhances the growth of axons from these neurons by
BCMA-dependent activation of the ERK and PI3-kinase/Akt signaling
pathways. This is the ﬁrst reported activity for APRIL in the nervous
system.Results
APRIL and BCMA are expressed in the developing hippocampus
We began our investigation of the potential functions of APRIL in
neural development by deﬁning when and where APRIL is expressed
in the developing hippocampus andwhether either of its two receptors
is expressed. We used qPCR to quantify the relative levels of APRIL,
BCMA and TACI mRNAs in whole hippocampi dissected from E18, P0,
P5 and P10 mice. Both APRIL and BCMA mRNAs were clearly detectedFig. 1. Expression of APRIL and BCMA in the developing hippocampus. Graphs of the levels of A
total RNA extracted fromE18, P0, P5 and P10hippocampi (mean± s.e.m., n=4 separate sets of
P10 hippocampi probed for GAPDH together with either APRIL (C) or BCMA (D). Lysates fromthroughout this period (Fig. 1A and B), but TACI mRNA was barely
detectable (not shown). Whereas the level of BCMA mRNA increased
signiﬁcantly over this period (P b 0.0001, E18 versus P10, one-way
ANOVA), there was no signiﬁcant change in the level of APRIL mRNA
(P N 0.05, E18 versus P10, one-way ANOVA).
Western analysis revealed bands corresponding to the pro and ma-
ture forms of APRIL (Fig. 1C) and BCMA (Fig. 1D) in lysates of hippocam-
pi dissected from E18, P0, P5 and P10 mice. Bands of the same sizes
were present in lysates of adult spleen used as positive control tissue
(Aggarwal, 2003). In accordance with the qPCR data, TACI protein was
barely detectable in lysates of cultured hippocampal neurons (not
shown).
To clarify which kind of cells express APRIL and BCMA in the devel-
oping hippocampus and their cellular distribution, we localized these
proteins by immunohistochemistry in hippocampal sections using the
same speciﬁc antibodies that recognized these proteins in the above
Western analysis. The sections were triple stained with the nuclear
marker TO-PRO®-3 Iodide, either the dendrite marker anti-MAP2 or
the axon marker anti-neuroﬁlament and either anti-APRIL (Fig. 2A) or
anti-BCMA (Fig. 2B). In sections of the hippocampus at P10, prominent
APRIL and BCMA labeling was evident in the pyramidal cell layers of
the CA1, CA2 and CA3 ﬁelds. High power images of CA1 show labeling
of the cell bodies of the pyramidal cells and particularly prominent
staining in the stratum radiatum,which consistsmostly of the dendrites
of pyramidal cells that are double labeled with anti-MAP2 antibodies.
Sections through the ﬁmbria and stratum oriens clearly revealed
anti-BCMA labeled ﬁbers that are doubled with anti-neuroﬁlament
antibodies and correspond in part to pyramidal cell axons that pro-
ject to the subiculum and lateral entorhinal cortex. Very similar pat-
terns for APRIL and BCMA were observed in hippocampal sections at
E18, P0 and P5 (not shown). Sections were unlabeled by secondary
antibodies alone and were unstained by anti-TACI antibodies (not
shown).APRIL promotes the growth of axons but not dendrites from cultured
pyramidal cells
To investigate the potential role of APRIL in hippocampal neuron
development, we established dissociated cultures from E18 mousePRILmRNA (A) and BCMAmRNA (B) relative to reference mRNAs for GAPDH and SDHA in
hippocampal tissue at each age). RepresentativeWestern blots of lysates of E18, P0, P5, and
spleen tissue were probed as positive control.
Fig. 2. Localization of APRIL and BCMA in the developing hippocampus. Frozen sections of
P10 hippocampus triple labeled with TO-PRO®-3 Iodide, anti-MAP-2 or anti-200 kD neu-
roﬁlament and either (A) anti-APRIL (B) or anti-BCMA. For each set, the upper panels
show a higher power image of CA1 (scale bars = 25 μm), the middle panels show lower
power images of the CA regions (scale bars= 200 μm) and the lower panel show a higher
power image of the ﬁmbria (scale bars = 25 μm). Abbreviations: rad, stratum radiatum;
py, stratum pyramidale; ﬁm, ﬁmbria; alv, alveus; ori, stratum oriens.
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cultures is the pyramidal cell. In agreement with others (Kaech and
Banker, 2006; Kaech et al., 2012), the overwhelming majority of
cells in these cultures are neurons (98.52% ± 0.22 of the cells are
stained with anti-MAP-2 and only 1.48% ± 0.22 of the cells stain
with anti-GFAP, which recognizes glial cells).
We examined the effect of APRIL on axon growth and dendrite
growth separately. To investigate whether APRIL affects axon growth,
the neurons were transfected with a green ﬂuorescent protein expres-
sion plasmid 2 days after plating and were treated with APRIL for 18 h
prior to ﬁxation and immunostaining for GFP. The axons of APRIL-
treated neurons were clearly longer than those in control cultures
(Fig. 3A, B and C). Measurement of axon length revealed highly signiﬁ-
cant increases in length in cultures supplementedwith APRIL compared
with control cultures (Fig. 3B) at APRIL concentrations of 10 ng/ml and
greater. Based on this dose response analysis, we used 100 ng/ml APRIL
in subsequent experiments. Neurons corresponding to the 100th, 75th,
50th and 25th percentiles in terms of axon length for control and APRIL-treated cultures are illustrated in Fig. 3C. In addition to enhancing axo-
nal extension from pyramidal cells in dissociated cultures, APRIL also
clearly increased the density and extent or neurite outgrowth from
E18 CA1 hippocampal explants after 3 days in culture (Fig. 3D).
Initial axon growth from pyramidal neurons was unaffected by
APRIL. There were no signiﬁcant differences in axon length between
control cultures and those treated with APRIL at the time of plating
after 24 h of incubation (57.96 ± 1.75 μm versus 56.74 ± 2.12 μm,
mean ± sem) and 48 h of incubation (134.80 ± 10.42 μm versus
135.12 ± 11.01 μm, mean ± sem). This initial lack of dependence on
APRIL is akin to the initial independence of axon extension from
newly differentiated PNS neurons to neurotrophins (Davies, 1989).
After 7 days in culture,MAP-2-positive dendrites arewell-developed
(Kaech and Banker, 2006; Kaech et al., 2012). To investigate whether
APRIL affects dendrite growth, neurons were transfected with pGFP 6
days after plating, treated with APRIL over a range of concentrations
and immunostained for GFP 18 h later. The dendrite arbors appeared
similar in APRIL-treated and control cultures (Fig. 3E). Quantiﬁcation
of the percentage of dendrites longer than 50 μm revealed that APRIL
at concentrations ranging from 10 to 1000 ng/ml caused no signiﬁcant
increases in dendrite elongation (Fig. 3F). Taken together, these in vitro
studies suggest that APRIL is able to selectively enhance axon growth,
but not dendrite growth, from developing hippocampal pyramidal cells.
BCMA is required for APRIL-promoted axon growth
Although BCMA is clearly expressed by pyramidal cells and TACI is
barely detectable, we carried out experiments to formally demonstrate
that the effects of APRIL on axon growth are mediated by BCMA by
manipulating the function of this receptor in hippocampal neurons cul-
tured with and without APRIL. To do this, we transfected 2-day cultures
of E18neuronswith a plasmid vector inwhich separate promoters drive
the expression of GFP and full-length or truncated BCMA proteins. After
transfection, the medium was changed to a medium with or without
APRIL and the cultures were ﬁxed and immunostained for GFP 18 h
later. The extent of axon growth from neurons overexpressing full-
length BCMA and grown in the absence of APRIL was comparable to
that from neurons treated with APRIL, and the extent of axon growth
from BCMA-overexpressing neurons was not further enhanced by
APRIL (Fig. 4A and B). The extent of axon growth from neurons express-
ing a signaling-defective BCMA mutant that is truncated at the 83
residue in the C-terminal (BCMA ΔC83) (Yang et al., 2005) was signiﬁ-
cantly reduced compared with control cultures, and the expression of
truncated BCMA prevented APRIL from promoting axonal elongation.
These results suggest that the axon growth-enhancing effect of APRIL
is mediated by BCMA.
The signiﬁcant reduction in axon elongation from pyramidal neu-
rons expressing BCMA ΔC83 could be due to an effect of BCMA on
axon growth independently of APRIL. However, the immunocytochem-
ical demonstration of APRIL in pyramidal cells raised the possibility that
these cells secrete APRIL in culture which could activate BCMA. To test
this possibility, we used ELISA to estimate the level of APRIL in culture
medium conditioned by pyramidal cells. After 3 days, the concentration
of APRIL in the medium was 1.55 ± 0.20 ng/ml (mean ± s.e.m., n = 3
separate culture experiments), suggesting that these cells secrete
APRIL in culture.
To test whether BCMA receptor activation by secreted APRIL affects
the extent of axon growth, we compared the axon length in cultures
treated with function-blocking antibodies to either anti-BCMA or anti-
APRIL or IgG obtained from the same species in which the antibodies
were raised. In these experiments, E18 hippocampal pyramidal cells
were initially cultured for 2 days prior to transfection with pGFP and
were treated with either of the function-blocking antibodies or control
IgG in the presence or absence of APRIL for 18 h prior toﬁxation and im-
munostaining for GFP. Anti-BCMA treatment caused a highly signiﬁcant
reduction in axon length compared with IgG-treated cultures (Fig. 4C),
Fig. 3. APRIL selectively enhances axonal growth from cultured hippocampal pyramidal neurons. (A–C) Axonal growth from E18 hippocampal pyramidal neurons after 3 days in vitro. The
neurons were transfected 2 days after plating with a plasmid expressing GFP and were treated with APRIL for the last 18 h of culture prior to ﬁxation and immunostaining for GFP.
(A) Representative neurons incubated without APRIL (Control) or treated with 100 ng/ml APRIL. Scale bar = 100 μm. (B) Axon length in control cultures and cultures treated with
APRIL at the concentrations indicated. (C) Camera lucida drawings of control neurons and neurons treated with 100 ng/ml APRIL. The neurons illustrated correspond to the 100th,
75th, 50th and 25th percentiles in terms of total neurite length for each condition. (D) Representative E18 CA1 explants incubated with and without APRIL (100 ng/ml) for 3 days before
labeling the emergent neurite with the ﬂuorescent vital dye calcein AM. Scale bar = 200 μm. (E–F) Dendrite growth from E18 hippocampal pyramidal neurons after 7 days in vitro. The
neurons were transfected with pGFP 6 days after plating and were incubated with and without APRIL for the last 18 h of culture prior to ﬁxation and immunostaining for GFP. (E) Rep-
resentative neurons incubatedwithout APRIL (Control) or treatedwith 100 ng/ml APRIL. Scale bar= 50 μm. (F) Bar chart of the percentage of dendrites longer than 50 μm in control cul-
tures and cultures treated with APRIL at the concentrations indicated. The data shown in B and F represent the mean ± s.e.m. of data compiled from N150 neurons per condition from at
least three separate experiments (*** indicates P b 0.0001, statistical comparison with control, Mann–Whitney U test).
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quite reach signiﬁcance (P = 0.068). However, in cultures in which
anti-APRIL was added at the time of plating, axon length was signiﬁ-
cantly shorter than in the corresponding IgG-treated control cultures
(828.7 ± 48.8 m versus 980.5 ± 54.3 m, mean ± s.e.m., n = 150 neu-
rons per condition from 3 separate experiments, p b 0.05). The anti-
BCMA and anti-APRIL antibodies completely inhibited the effects of ex-
ogenous APRIL on axonal growth, indeed axon length in these
cultures was signiﬁcantly less than in IgG-treated cultures (Fig. 4C).Taken together, these results suggest that APRIL secreted by hippocam-
pal pyramidal cells signiﬁcantly enhanced axonal growth from these
neurons in culture.
APRIL enhances axonal growth by activating ERK1 and ERK2
To elucidate themolecularmechanismunderlying the enhancement
of axon growthbyAPRIL, we explored common links in intracellular sig-
naling between the control of neurite growth and APRIL signaling in the
Fig. 4. BCMA mediates APRIL-promoted axonal outgrowth. (A) Representative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitrowith plasmids expressing
either GFP alone or GFP together with either wild-type BCMA or truncated BCMA (BCMA ΔC86). After transfection, the neurons were cultured for a further 18 h with and without APRIL
(100 ng/ml) before GFP immunostaining. Scale bar= 100 μm. (B) Bar chart of axonal length under the experimental conditions illustrated in A. (C) Bar chart of axonal length of neurons
cultured in the presence or absence of 3 μg/ml of anti-BCMA or 1.5 μg/ml of anti-APRIL with or without APRIL (100 ng/ml). The mean ± s.e.m. of data obtained from N150 neurons per
condition compiled from at least three separate experiments are shown (*** indicates P b0.0001, statistical comparison with control, Mann–Whitney U test).
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by APRIL in myeloma cells (Moreaux et al., 2004) and adipose-derived
stem cells (Zonca et al., 2012) and byNGF in PC12 cells and sympathetic
neurons where it contributes to the neurite growth response to
neurotrophins (Atwal et al., 2000; Gomez and Cohen, 1991; Goold and
Gordon-Weeks, 2005; O'Keeffe et al., 2008; Thompson et al., 2004).
To investigate whether MEK/ERK signaling in the MAP kinase cas-
cade contributes to APRIL-promoted axon elongation fromhippocampal
pyramidal cells, we ﬁrst tested whether APRIL activates ERK1 and ERK2
in these neurons. In these experiments, we initially cultured E18 pyrami-
dal cells for 3 days before treating them with APRIL. This treatment
caused rapid increases in the levels of phospho-ERK1 and phospho-
ERK2 within 15 min that remained elevated for at least 60 min (Fig. 5A
and B), demonstrating that APRIL causes rapid ERK1/ERK2 activation in
the pyramidal cells.
To ascertain if activation of ERK1 and ERK2 contributes to APRIL-
promoted axon growth, we examined whether PD98059, a selective in-
hibitor of MEK1 and MEK2, the kinases that phosphorylate and activate
ERK1 and ERK2 (Touyz et al., 2002), could prevent the APRIL-promoted
axon growth. In these experiments, the neuronswere transfectedwith a
GFP plasmid 2 days after plating and were then pretreated for 2 h with
PD98059 before adding APRIL and quantifying axon length 18 h later.
Axons were signiﬁcantly longer in cultures treated with APRIL alonecompared with control cultures, and whereas axon length in cul-
tures that received PD98059 alone was not signiﬁcantly different
from that in control cultures, PD98059 pretreatment prevented the
axon growth-enhancing effect of APRIL (Fig. 5C and D). This suggests
that MEK/ERK signaling plays a crucial role in mediating the effect of
APRIL on axon growth from developing pyramidal cells.APRIL enhances axonal growth by activating PI-3 kinase/Akt signaling
Another common link in intracellular signaling between neurite
growth and APRIL signaling in the immune system is the phos-
phatidylinositol 3-kinase (PI-3 kinase)/Akt (also known as protein
kinase B, PKB) pathway. Class I PI-3 kinases are activated by several
kinds of cell surface receptors, including receptor tyrosine kinases,
such as the Trk family of neurotrophin receptors. The subsequent
production of phosphatidylinositol 3,4,5 triphosphates activates
the serine/threonine Akt kinases, which contribute to the neurite
growth-promoting effects of neurotrophins (Atwal et al., 2000;
Cosker and Eickholt, 2007; Kuruvilla et al., 2000; Read and Gorman,
2009). APRIL activates PI-3 kinase in myeloma cells (Moreaux et al.,
2004), B-cell lymphoma (Gupta et al., 2009) and human adipose-
derived stem cells (Zonca et al., 2012).
Fig. 5.APRIL promotes axonal growth by activating ERK1 and ERK2. (A) RepresentativeWestern blots probed for phospho-ERK1/ERK2 and total ERK1/ERK2 of lysates of E18 hippocampal
neurons of treated with 100 ng/ml APRIL for the times indicated after ﬁrst culturing the neurons for 3 days. (B) Densitometric quantiﬁcation of levels of phospho-ERK1/phospho-ERK2
relative to total ERK1/total ERK2 from 3 separate Western blot experiments (mean ± s.e.m., *** indicates P b 0.0001, statistical comparison with control, Mann–Whitney U test). (C) Im-
ages of representative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitrowith a plasmid expressing GFP andwere treated with 10 μMof PD98059 2 h prior to
incubation for 18 h with and without APRIL (100 ng/ml) before GFP immunostaining. Separate cultures were treated with APRIL after transfection and control cultures received neither
PD98059 nor APRIL. Scale bar=100 μm. (D) Bar chart of the axonal growthunder the experimental conditions illustrated in C. Themean± s.e.m. of data obtained from N 150neurons per
condition compiled from at least three separate experiments are shown (*** indicates P b 0.0001 and n.s., non-signiﬁcant, statistical comparison with control, Mann–Whitney U test).
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axon growth,we ﬁrst examinedwhether the selective PI-3 kinase inhib-
itor LY294002 (Vlahos et al., 1994) was able to prevent the APRIL-
promoted axon elongation. In these experiments, the neurons were
transfectedwith a GFP plasmid 2 days after plating andwere pretreated
for 2 h with LY294002 before adding APRIL to the culture medium and
quantifying axon length 18 h later. Whereas axon length in cultures
that received LY294002 alone was not signiﬁcantly different from that
in control cultures, LY294002 completely prevented the axon growth-
enhancing effect of APRIL (Fig. 6A and B). To conﬁrm the results of
these pharmacological experiments, we transfected pyramidal cells
with a construct that expresses both GFP and a dominant-negative
formof thep85α regulatory subunit of PI-3 kinase that lacks the binding
domain for the p110 catalytic subunit. The p85α mutant had a small,
signiﬁcant effect on axon extension from neurons not exposed to exog-
enous APRIL, and completely eliminated the axon growth-enhancing
effect of exogenous APRIL (Fig. 6C and D). Taken together, these results
suggest that PI3-kinase signaling is required for the effect of APRIL on
axon growth.
To determine the involvement of Akt signaling in APRIL-promoted
axon growth, we ﬁrst investigated whether APRIL treatment activates
Akt. E18 pyramidal cells were initially cultured for 3 days prior to
APRIL treatment.Western analysis showed that APRIL caused a rapid in-
crease in the level phospho-Akt within 15 min, reaching a peak 30 min
after APRIL addition. The level of phospho-Akt remained signiﬁcantly
elevated in APRIL-treated cultures for at least 60 min (Fig. 7A and B).
To test whether Akt signaling contributes to APRIL-promoted axongrowth, we ﬁrst examined whether a selective dual Akt1/Akt2 kinase
inhibitor (Zhao et al., 2008) was able to prevent the increase in axon
elongation promoted by APRIL. E18 pyramidal cells were transfected
with pGFP 2 days after plating and were pretreated for 2 h with the
Akt1/Akt2 inhibitor before adding APRIL to the culture medium and
quantifying the axon length 18 h later. Whereas axon length in cultures
that received the Akt1/Akt2 inhibitor alone was not signiﬁcantly differ-
ent from that in control cultures, the Akt1/Akt2 inhibitor completely
prevented the axon growth-enhancing effect of APRIL (Fig. 7C and D).
As further conﬁrmation of these results, we transfected pyramidal
cells with a plasmid that expresses both GFP and an Akt construct
with loss-of-function mutations in its active site. Expression of the Akt
mutant had no signiﬁcant effect on axon extension in the absence of ex-
ogenous APRIL, and completely eliminated the axon growth-enhancing
effect of exogenous APRIL (Fig. 7E and F). Taken together, these results
suggest that Akt signaling is required for the effect of APRIL on axon
growth.
APRIL enhances axonal growth by inactivating glycogen synthase
kinase-3β
Glycogen synthase kinase-3 (GSK-3) proteins are among the many
substrates of Akt kinases, and have been implicated in the regulation
of multiple aspects of neural development (Hur and Zhou, 2010), in-
cluding the control of axon growth from developing sensory and hippo-
campal neurons (Kim et al., 2006; Zhou et al., 2004). The two isoforms of
GSK-3, GSK-3α and GSK-3β, can be phosphorylated on serine-21 and
Fig. 6.APRIL-promoted axonal growth depends on PI-3 kinase activation. (A) Images of representative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitrowith
a plasmid expressing GFP and were treated with 10 μM of LY294002 2 h prior to a further 18 h of incubation with and without APRIL (100 ng/ml) before GFP immunostaining. Separate
cultures were treatedwith APRIL after transfection and control cultures received neither LY294002 nor APRIL. (B) Bar chart of the axonal growth under the experimental conditions illus-
trated in A. (C) Images of representative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitrowith plasmids expressing either GFP alone or GFP together with a
dominant-negative formof p85α regulatory subunit of PI-3 kinase (p85α-DN). After transfection, the neuronswere cultured for a further 18 hwith andwithout APRIL (100 ng/ml) before
GFP immunostaining. (D) Bar chart of the axonal growth under the experimental conditions illustrated inC. Themean± s.e.m. of data obtained fromN150neurons per condition compiled
from at least three separate experiments are shown in B andD (** indicates P b 0.001, *** indicates P b 0.0001 and n.s., non-signiﬁcant, statistical comparisonwith control,Mann–Whitney
U test). Scale bars = 100 μm.
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inactivation of GSK-3, and several studies suggest that inactivated GSK-
3 promotes axon elongation from cultured sensory and hippocampal
neurons by regulating themolecularmachinery that controls actin rear-
rangement and microtubule assembly (Kim et al., 2006; Kumar et al.,
2009; Namekata et al., 2012; Yoshimura et al., 2005; Zhou et al.,
2004). To determine if treating hippocampal neurons with APRIL leads
to GSK-3 phosphorylation, we cultured E18 pyramidal cells for 3 days
before treating them with APRIL. Western blot analysis revealed that
APRIL caused a rapid increase in the phosphorylation of phospho-S9
GSK-3β thatwas sustained for at least 60min (Fig. 8A and B), but caused
no change in the level of phospho-S21 GSK-3α.
To evaluate the participation of GSK-3β in the axon growth-
promoting effects of APRIL, we studied the effect of expressing a consti-
tutively active form of GSK-3β in hippocampal neurons. Neurons that
were transfected with a construct that expresses GFP together with aconstitutively active GSK-3β protein (GSK-3β S9A) extended axons
that were not signiﬁcantly different in length from those transfected
with a GFP-expressing construct. However, expression of the GSK3β
S9A mutant completely eliminated the axon growth-enhancing effect
of APRIL (Fig. 8C and D). These results suggest that the effect of APRIL
on axon growth is mediated by GSK-3β inactivation.
Discussion
We have described and characterized the ﬁrst known activity for
APRIL in the nervous system. In culture, recombinant APRIL selectively
enhanced axon elongation from neonatal hippocampal pyramidal
cells, but did not affect the elongation of dendrites from these neurons.
Several observations suggest that this effect of APRIL was mediated by
one of its receptors, BCMA. First, BCMA mRNA and protein were clearly
detectable in extracts of the developing hippocampus, and BCMA was
Fig. 7.APRIL promotes axonal growth by activating Akt signaling. (A) RepresentativeWestern blot probed for phospho-Akt and total Akt in lysates of E18 hippocampal neurons of treated
with 100 ng/ml APRIL for the times indicated after ﬁrst culturing the neurons for 3 days. (B) Densitometric quantiﬁcation of levels of phospho-Akt relative to total Akt from 3 separate
Western blot experiments (mean± s.e.m., *** indicates P b 0.0001, statistical comparison with control, Mann–WhitneyU test). (C) Images of representative E18 hippocampal pyramidal
neurons thatwere transfected after 2 days in vitrowith a plasmid expressingGFP andwere treatedwith 5 μMof theAkt1/2 inhibitor 2 h prior to a further 18h incubationwith andwithout
APRIL (100 ng/ml) before GFP immunostaining. Separate cultureswere treatedwith APRIL after transfection and control cultures received neither the inhibitor nor APRIL. (D) Bar chart of
the axonal growth under the experimental conditions illustrated in C. (E) Images of representative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitro with
plasmids expressing either GFP alone or GFP together with the Akt1 K179M T308A S473A mutant (Akt1-mut). After transfection, the neurons were cultured for a further 18 h with
andwithout APRIL (100 ng/ml) beforeGFP immunostaining. (F) Bar chart of the axonal growth under the experimental conditions illustrated in E. The data shown inD and F are compiled
from N150 neurons per condition from at least three separate experiments (mean ± s.e.m., *** indicates P b 0.0001 and n.s. non-signiﬁcant, statistical comparison with control, Mann–
Whitney U test). Scale bars = 100 μm.
31C. Osório et al. / Molecular and Cellular Neuroscience 59 (2014) 24–36
Fig. 8. APRIL promotes axonal growth by activating GSK-3β signaling. (A) RepresentativeWestern blots probed for phospho-GSK-3α, phospho-GSK-3β and total GSK-3β in lysates of E18
hippocampal neurons treated with 100 ng/ml APRIL for the times indicated after ﬁrst culturing the neurons for 3 days. (B) Densitometric quantiﬁcation of levels of phospho-GSK-3β rel-
ative to total GSK-3β from 3 separate Western blot experiments (mean ± s.e.m., *** indicates P b 0.0001, statistical comparison with control, Mann–Whitney U test). (C) Images of rep-
resentative E18 hippocampal pyramidal neurons that were transfected after 2 days in vitro plasmids expressing either GFP alone or GFP together with the GSK3β S9A mutant. After
transfection, the neurons were cultured for a further 18 h with and without APRIL (100 ng/ml) before GFP immunostaining. (D) Bar chart of the axonal growth under the experimental
conditions illustrated inC. Themean± s.e.m. of data obtained from N150neurons per condition compiled fromat least three separate experiments are shown inD (*** indicates P b 0.0001
and n.s., non-signiﬁcant, statistical comparison with control, Mann–Whitney U test). Scale bars = 100 μm.
32 C. Osório et al. / Molecular and Cellular Neuroscience 59 (2014) 24–36localized to pyramidal cells by immunohistochemistry. In contrast, TACI,
the alternative TNFRSF member through which APRIL signals (Bossen
and Schneider, 2006), was barely detectable in the hippocampus.
Second, function-blocking anti-BCMA antibodies inhibited the axon
growth-promoting effects of recombinant APRIL. Third, expression of a
truncated, non-functional BCMA mutant in hippocampal pyramidal
cells inhibited the axon growth-promoting effects of APRIL. Fourth,
overexpression of full-length BCMA promoted axon elongation just as
effectively as recombinant APRIL. Finally, axon growth was not further
enhanced by treating BCMA-overexpressing neurons with APRIL, sug-
gesting that enhancing BCMA signaling independently of exogenous
APRIL mimics the effect of APRIL treatment.
While BAFF also binds to BCMA (Day et al., 2005), several observa-
tions suggest that APRIL is a potentially relevant ligand for BCMA in
the developing hippocampus. First, APRIL mRNA and protein were de-
tectable in hippocampal extracts throughout the period of development
pyramidal cells extend axons in vivo. Second, APRIL was secreted by
hippocampal pyramidal cells in culture. Third, function-blocking anti-
APRIL antibodies signiﬁcantly reduced axon elongation from these
neurons, at least when added to the medium at the time of plating,
which suggests that biologically active APRIL is secreted in sufﬁcient
quantities by cultured hippocampal pyramidal cells to affect axon
elongation.
Our immunohistochemical studies suggest that both APRIL and
BCMA proteins are localized to pyramidal cells in the developinghippocampus. This raises the possibility that APRIL could act on these
neurons by an autocrine and/or paracrine mechanism in vivo. Co-
expression of APRIL and BCMA has been reported in mesenchymal
cells of the placenta (Langat et al., 2008), and experimental evidence
for APRIL/BCMA autocrine signaling has been obtained from studies of
normal and malignant B cells (Chiu et al., 2007; He et al., 2004). Auto-
crine/paracrine signaling involving APRIL and BCMA could inﬂuence
the development of hippocampal pyramidal cells in an analogous
fashion to autocrine/paracrine signaling involving neurotrophins
(Boukhaddaoui et al., 2001; Horch and Katz, 2002). It is possible that
the level of expression of APRIL and BCMA in hippocampal pyramidal
cells, and hence the extent of APRIL/BCMA signaling, could be regulated
by factors acting on these neurons during development or by particular
patterns of neural activity in these neurons. For these reasons, it will be
informative to determine how the expression of APRIL and BCMA are
regulated in hippocampal pyramidal cells during development, as this
might provide a better understanding of how APRIL/BCMA signaling
and its effects on axon growth are integrated with other aspects of hip-
pocampal development. APRIL and BCMA are also expressed by other
neurons in the hippocampus, and while there is a signiﬁcant increase
in the level of BCMA mRNA in the hippocampus unaccompanied by a
parallel increase in APRIL mRNA levels during perinatal development,
these levels represent the sum total of changes in multiple populations
of neurons, some of which make afferent or efferent connections with
neurons outside the hippocampus.
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phosphorylation andhence activation of ERK1, ERK2 andAkt in cultured
hippocampal pyramidal neurons. These kinases have also been reported
to be activated by APRIL in several other cell types (Gupta et al., 2009;
Moreaux et al., 2004; Zonca et al., 2012). These kinases have also been
implicated in regulating neurite growth from a variety of neurons and
neuronal cell lines in response to neurotrophins (Atwal et al., 2000;
Cosker and Eickholt, 2007; Gomez and Cohen, 1991; Goold and
Gordon-Weeks, 2005; Hafner et al., 2012; Kuruvilla et al., 2000;O'Keeffe
et al., 2008; Read and Gorman, 2009; Thompson et al., 2004). Impor-
tantly, we have shown that the axon growth-promoting effect of recom-
binant APRIL is abolished by pharmacological inhibition of either MEK1
and MEK2 (the kinases that lie upstream of ERK1 and ERK2 in the MAP
kinase signaling pathway), PI-3 kinase (enzyme that generates phos-
phatidylinositol 3,4,5 triphosphates which in turn activate Akt) or Akt
and by expression of a dominant-negative versions of Akt and the regu-
latory subunit PI-3 kinase. These ﬁndings suggest that both MAP kinase
signaling and PI-3 kinase/Akt signaling are required for the axon
growth-promoting action of APRIL.
Finally, we demonstrated that GSK-3β, one of Akt's many substrates,
becomes rapidly phosphorylated on serine 9 in hippocampal pyramidal
neurons following APRIL treatment. Phosphorylation on this residue re-
sults in inactivation of GSK-3 (Cross et al., 1995), and several studies
suggest that inactivated GSK-3β promotes axon elongation from cul-
tured sensory and hippocampal neurons by regulating the molecular
machinery that controls actin rearrangement andmicrotubule assembly
(Kim et al., 2006; Kumar et al., 2009; Namekata et al., 2012; Yoshimura
et al., 2005; Zhou et al., 2004). Our demonstration that expression of a
constitutively active mutant of GSK-3β prevents the axon growth-
promoting action of APRIL suggests that this depends on GSK-3β
inactivation.
APRIL and BCMA are potent activators of NF-κB family of transcrip-
tion factors (Hatzoglou et al., 2000; Kern et al., 2004). NF-κB signaling
either promotes or inhibits neurite growth depending on the mecha-
nism of NF-κB activation and phosphorylation status of the p65 NF-κB
subunit (Gutierrez and Davies, 2011). Although we have not explored
whether APRIL affects NF-κB signaling in hippocampal pyramidal neu-
rons, it will be interesting in future work to ascertain whether NF-κB
signaling plays a role in modulating APRIL-promoted axon growth.
Our present demonstration that APRIL selectively promotes axon
growth from developing hippocampal pyramidal neurons adds to the
growing body of work implicating members of the TNFSF in regulating
the growth and branching of neural processes during development
(Desbarats et al., 2003; Gavalda et al., 2009; Gutierrez et al., 2008,
2013; Kisiswa et al., 2013; Neumann et al., 2002; O'Keeffe et al., 2008;
Zuliani et al., 2006). It will be important in future studies to ascertain
the physiological relevance of our ﬁndings by studying relevant
aspects of the phenotype of mice possessing null mutations of the
APRIL and BCMA genes. Also, it will be important to explore whether
APRIL and BCMAplay a role in regulating the growth of neural processes
from neurons elsewhere in the developing nervous system.
Experimental methods
Animals
This study was conducted on tissues obtained from CD1 mice
(Mus musculus). Breeding and housing were approved by the Cardiff
University Ethical Review Board and was performed within the
guidelines of the Home Ofﬁce Animals (Scientiﬁc Procedures) Act,
1986.
Quantitative PCR
The levels of APRIL and BCMA mRNAs were quantiﬁed by RT-QPCR
relative to a geometric mean of mRNAs for the house keeping enzymesglyceraldehyde phosphate dehydrogenase (GAPDH) and succinate de-
hydrogenase (SDHA). Total RNA was extracted from whole hippocam-
pus with the RNeasy Mini Lipid extraction kit (Qiagen, Crawely, UK),
and 5 μl was reverse transcribed for 1 h at 45 °C using the AfﬁnityScript
kit (Agilent, Berkshire, UK) in a 25 μl reaction according to the
manufacturer's instructions. 2 μl of cDNA was ampliﬁed in a 20 μl reac-
tion volume using Brilliant III ultrafast QPCR master mix reagents
(Agilent, Berkshire, UK). QPCR products were detected using dual-
labeled (FAM/BHQ1) hybridization probes speciﬁc to each of the
cDNAs (MWG/Euroﬁns, Ebersberg, Germany). The PCR primers were:
APRIL forward, 5′-CTG TCC TTC CTA GAT AAT G-3′ and reverse, 5′-CTA
GTG ACA CTC TGA CAC-3′; BCMA forward, 5′-TGA CCA GTT CAG TGA
AAG G-3′ and reverse, 5′-GGG TTC ATC TTC CTC AGC-3′; GAPDH for-
ward, 5′-GAG AAA CCT GCC AAG TAT G-3′ and reverse, 5′-GGA GTT
GCT GTT GAA GTC-3′; SDHA forward, 5′-GGA ACA CTC CAA AAA CAG-
3′ and reverse, 5′-CCA CAG CAT CAA ATT CAT-3′. Dual-labeled probes
were: APRIL, FAM-CAC CAA ATT CTC CTG AGG CT-BHQ1; BCMA, FAM-
CGT ACA CGG TGC TCT GGA TCT TCT T-BHQ1; GAPDH, FAM-AGA CAA
CCT GGT CCT CAG TGT-BHQ1; SDHA, FAM-CCT GCG GCT TTC ACT TCT
CT-BHQ1. Forward and reverse primers were used at a concentration
of 150 nM each and dual-labeled probes were used at a concentration
of 300 nM. PCR was performed using the Mx3000P platform (Agilent,
Berkshire, UK) using the following conditions: 45 cycles of 95 °C for
12 s and 60 °C for 35 s. Standard curves were generated in every 96-
well plate, for each cDNA for every real time PCR run, by using serial
three-fold dilutions of reverse transcribed adult mouse brain total RNA
(Ambion, Paisley, UK). Three separate sets of dissections of the hippo-
campi were carried to harvest tissue at each of the following ages:
E18, P0, P5 and P10.
Immunohistochemistry
Brains were ﬁxed in 4% paraformaldehyde for 24 h and then
cryoprotected in 30% sucrose before being frozen. OCT embedded
tissues were snap frozen in isopentene (Sigma-Aldrich, Dorset, UK),
cooled with dry ice and serially sectioned at 15 μm. Sections were
mounted onto electrostatic charged slides (Leica Microsystems, Peter-
borough, UK), blocked with 5% goat serum and 2% bovine serum albu-
men containing 0.1% Triton X-100 (Sigma-Aldrich, Dorset, UK) in
phosphate-buffered saline (PBS) for 1 h at room temperature, and
then incubated for 18 h at 4 °C with primary antibodies dissolved in
blocking buffer diluted 5 fold. Primary antibodies were: rabbit anti-
APRIL (1:200, Abcam, Cambridge, UK, ab64967), rabbit anti-BCMA
(1:200, Abcam, Cambridge, UK, ab5972), rabbit anti-TACI (1:200,
Abcam, Cambridge, UK, ab79023), chicken anti-200 kD neuroﬁlament
Heavy (1:250, Abcam, Cambridge, UK, ab4680) and chicken anti-
MAP2 (1:250, Abcam, Cambridge, UK, ab5392). After incubation,
sections were subsequently washed three times in PBS, incubated for
1 h with biotin-conjugated anti-rabbit IgG (1:500, Vector Laboratories,
Cambridgeshire, UK) and Alexa Fluor 546 conjugated goat anti-
chicken IgG (1:500, Invitrogen, Paisley, UK). After a further incubation
for 30 min with DyLight 488 conjugated streptavidin (1:500, Vector
Laboratories, Cambridgeshire, UK) in blocking buffer diluted 5 fold,
slices were washed with PBS three times and incubated for 10 min
with TO-PRO®-3 Iodide staining (1:10,000 Invitrogen, Paisley, UK) for
counterstaining off the nuclei. The slides were then washed three times
with PBS (5 min per wash) and were mounted with VECTASHIELD®
Mounting Media (Vector Laboratories, Cambridgeshire, UK). Images
were obtained using a Zeiss Axioplan confocal microscope (Zeiss,
Cambridge, UK). Negative controls (no primary antibody) were also set
up.
Immunoblotting
For the immunoblotting either dissected hippocampi or neurons cul-
tured at high density (200,000 cells/well) were lysed in ice-cold RIPA
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cocktail mix (Sigma-Aldrich, Dorset, UK) and insoluble debris was re-
moved by centrifugation. Equal quantities of protein were separated
on 10% SDS-PAGE gels and were transferred to PVDF membranes
using the BioRad TransBlot (BioRad, Hertfordshire, UK). The blots
were probed with rabbit anti-APRIL (1:200, Poway, CA, USA, Cat. No.
2415), rabbit anti-BCMA (1:200, Abcam, Cambridge, UK, ab5972), rabbit
anti-TACI (1:200, Abcam, Cambridge, UK, ab79023), chicken anti-
GAPDH (1:2000, Abcam, Cambridge, UK, ab83956), rabbit anti-
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1:1000, Cell Sig-
naling Technology, Danvers, MA, USA, 9101), rabbit anti-p44/42
MAPK (Erk1/2) (1:1000, Cell Signaling Technology, Danvers, MA,
USA, 9102), rabbit anti-Phospho-Akt (Ser473) (1:1000, Cell Signal-
ing Technology, Danvers, MA, USA, 4060), rabbit anti-Akt (1:1000,
Cell Signaling Technology, Danvers, MA, USA, 4685), rabbit anti-
phospho-GSK-3α/β (Ser21/9) (1:1000, Cell Signaling Technology,
Danvers, MA, USA, 9331) andmouse anti-GSK-3 (1:1000, Cell Signal-
ing Technology, Danvers, MA, USA, 9832). Binding of the primary
antibodies was visualized with HRP-conjugated donkey anti-rabbit,
anti-mouse or anti-chicken secondary antibodies (1:5000; rabbit
W4011, mouse W4021, Promega, Southampton, UK, and 1:5000;
chickenHRP Abcam, ab16349 Cambridge, UK,) and Chemiluminescence
Luminol Reagent (Santa Cruz Biotechnology, CA, USA). Densitometry
was carried out using Gel-Pro Analyzer 32 program (Media Cybernetics,
USA).ELISA (enzyme-linked immunosorbent assay)
Hippocampal cultures were plated in 3 wells of a 24-well plate with
a density of 200,000 cells per well. After 3DIVs, the supernatantwas col-
lected, centrifuged to remove debris, and stored at−80 °C until further
use. Sampleswere quantiﬁed using an ELISA kit for APRIL protein (USCN
Life Science Inc., rP91750Mu01, Houston, TX, USA) according to the
manufacturer's instructions.Neuron culture
Hippocampi were dissected from embryonic day 18 (E18) CD1
mouse fetuses, and were triturated to produce a single cell suspension
following trypsin digestion (Worthington, Lakewood, USA) and DNase
I treatment (Roche Applied Science, East Sussex, UK). The neurons
were plated on plastic dishes coated with poly-L-lysine (Sigma-Aldrich,
Dorset, UK) at a density of 50,000 cells/cm2 and were cultured in
Neurobasal A (Invitrogen, Paisley, UK) supplemented with 2% B27
(Invitrogen, Paisley, UK), 0.5 mM GlutaMAX I (Invitrogen, Paisley, UK),
100 units/ml penicillin and 100 g/ml streptomycin (Gibco BRL, Crewe,
UK). The cultures were incubated at 37 °C in a humidiﬁed atmosphere
containing 5% CO2.Neuronal transfection
After 2 or 6 days in vitro, the neurons were transfected with expres-
sion vectors using lipofectamine 2000 (Invitrogen, Paisley, UK) accord-
ing to themanufacturer's instructionswithmodiﬁcations. Brieﬂy, 1.2 μg
of DNAwasmixedwith 4 μl of lipofectamine. After 20min, this mixture
was added to the cultures. After 3 h, the cultureswere thenwashedwith
culture medium, at which point recombinant human APRIL was added
(R&D Systems, Abingdon, UK) and the neurons were maintained in
culture for further 18 h. Chemical inhibitors (PD98059, Sigma-P215,
LY294002 hydrochloride, Sigma-L9908 and Akt1/2 kinase inhibitor
A6730, Sigma-Aldrich Company, Dorset, UK) were added 2 h before
incubation of recombinant APRIL. Function-blocking antibodies
(mouse anti-BCMA, MAB5931 and human anti-APRIL, MAB5860, R&D
Systems, Abingdon, UK) were added after transfection.Expression vectors and report constructs
The vector expressing copGFP (pCDH-CMV-MCS-EF1-copGFP) was
obtained fromCambridge Bioscience (Cambridge, UK). Vectors express-
ing murine BCMA and BCMA ΔC83 were kindly provided by Adrian T.
Ting (Yang et al., 2005). The BCMA mBCMA ΔC83 sequences were
cloned into the HindIII and NotI sites of the vector pCDNA3.1. pCDH-
CMV-mBCMA-EF1-copGFP and pCDH-CMV-mBCMA ΔC83-EF1-copGFP
were made by excising the respective cDNA encoding sequences from
pCDNA3.1 and inserting them into the NheI and NotI sites of the vector
pCDH-CMV-MCS-EF1-copGFP.
To generate the construct that expresses GFP together with a
dominant-negative form of the p85α regulatory subunit of PI-3 ki-
nase, the sequence of p85α that lacks the binding domain for the
p110 catalytic subunit (Addgene, Cambridge, MA, USA, plasmid
13432, deposited by C. R. Kahn, ref. Taniguchi et al., 2006) was cloned
into the copGFP vector. To generate the construct that expresses GFP
together with Akt1 that possesses loss-of-function mutations in its
active site, the sequence of Akt1 that has the following substitutions
K179M, T308A and S473A (Addgene, Cambridge, MA, USA, plasmid
9031, deposited by W. R. Sellers, ref. Ramaswamy et al., 1999) was
cloned into the copGFP vector. To generate the construct that expresses
GFP together with a constitutively active mutant of GSK-3β, the se-
quence of GSK-3β that has S9A substitution (Addgene, Cambridge,
MA, USA, plasmid 14754, deposited by J. Woodgett, ref. Stambolic and
Woodgett, 1994) was cloned into the copGFP vector.
Analysis of axon and dendrite growth
18 h after transfection, the neuronswere ﬁxed for 30min in 4% para-
formaldehyde, permeabilized for 15min at room temperaturewith 0.5%
Triton X-100 in PBS and blocked for 1 hwith 10% goat serum in PBS con-
taining 0.1% Triton X-100. The neurons were then incubated for 1 h at
room temperature with primary antibody (anti-Cop/turbo GFP, 1:250,
Origene Technologies, Rockville, MD, USA) in PBS containing 10% goat
serum and 0.1% Triton X-100. After washing with PBS, the cultures
were incubated with an appropriate secondary antibody (Alexa
Fluor488 conjugated goat anti-mouse IgG, 1:500, Invitrogen, Paisley,
UK) in PBS containing 10% goat serum and 0.1% Triton. Labeled neurons
were visualized using an Axioplan confocal microscope (Zeiss). For
every experimental condition in each experiment, images of at least
150 neurons were digitally acquired.
For the analysis of axonal length, hippocampal neurons were
transfected with GFP-plasmids after 2 days in vitro and were ﬁxed
after 3 days in vitro in 4% paraformaldehyde for 30 min. Axonal length
was measured using ImageJ software (for each axon, the “segmented
line tool” was repeatedly used to deﬁne a line segment corresponding
to the axon whose length was subsequently measured in the program).
The analysis of dendritemorphologywas performed as described previ-
ously (Salama-Cohen et al., 2005). Brieﬂy, for each neuron, the number
of dendrites that crossed a circle of radius of 50 μm centered at the cell
soma was divided by the total number of primary dendrites and the
quotient was expressed as a percentage. The mean and standard errors
of these percentages are plotted.
Explant cultures
Explant cultures of the CA1 region of the hippocampus were es-
tablished in a 3-dimensional matrix of Matrigel (BD Biosciences) along
the lines described for collagen gels (Lumsden and Davies, 1983). A tis-
sue chopper was used to obtain 350 μm thick hippocampal slices and
CA1 was dissected from these slices using tungsten needles. A bed of
Matrigel (BD Biosciences)was kept on ice prior to use to avoid polymer-
ization. A bed of 20 μl of Matrigel was pipetted into wells of 4-well
dishes, which were placed in a 37 °C incubator to polymerize before
transferring the explants to these beds. A further 20 μl of Matrigel was
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for a further 15min to polymerize theMatrigel, afterwhich2ml of com-
plete neurobasal medium was added to each dish. After 3 days of cul-
ture, the emergent neurites were labeled with the ﬂuorescent vital
dye calcein AM (Invitrogen), and the explants were imaged by confocal
microscopy.Statistical analysis
Pair-wise comparisonsweremade using Student's t-test (two tailed).
For non-parametricmultiple comparisons theMann–WhitneyU testwas
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